vTv Therapeutics Inc.: Samsara BioCapital, L.P. amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Samsara BioCapital, L.P. filed an amended Schedule 13D with the SEC (accession 0001699737-26-000024) updating its stake in vTv Therapeutics Inc. The filing signals a change in the investor's position or intentions regarding the clinical-stage biotech. The amendment matters because 13D filings are required for investors holding more than 5% of a company and often precede activist or strategic moves. Investors will watch for further disclosures detailing the size and direction of Samsara's stake and any stated plans for the company.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Samsara BioCapital, L.P., vTv Therapeutics Inc.